22 October 2024 The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain. 21 October 2024
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Pharmaceutical Research and Manufacturers of America (PhRMA) says it has submitted comments to the Office of the United States Trade Representative (USTR) to inform the agency’s 2025 National Trade Estimate (NTE) Report on Foreign Trade Barriers. 21 October 2024
“The new key figures from the NZa show that Dutch expenditure on expensive medicines remains stable,” says Mark Kramer, chairman of the Association of Innovative Medicines (VIG), adding: “That is good news from a social perspective.” 21 October 2024
The Greek pharmaceutical industry is grappling with severe underfunding, as recent government adjustments fall short of resolving a critical hospital drug financing gap. 21 October 2024
Professional investors are a fascinating group of individuals, enjoying an incredibly direct link between results and reward, so a lot can be learned from understanding how they focus effort, writes Brian McGee, partner at Novasecta, in an Expert View piece. 18 April 2019
South Korea CNS medicines specialist SK Biopharmaceuticals and twoXAR, a US artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC). 18 April 2019
In Houston, Texas, scientists at the MD Anderson Cancer Center say they have discovered a new vulnerability in and potential treatment pathway for triple negative breast cancers (TNBC). 18 April 2019
A successful Phase II trial has led Indian pharma company Zydus Cadila to move its HIF-PH inhibitor desidustat into late-stage development. 17 April 2019
Brent Saunders, the chief executive and chairman of Ireland-headquartered drugmaker Allergan, will suddenly be feeling a lot better ahead of the company’s annual meeting of shareholders on May 1. 17 April 2019
Canada-based Canopy Growth is the world’s largest cannabis company, by market cap, and it aspires to be a world leader in developing the drug as a medicine. 17 April 2019
At its annual press conference in Ingelheim, just outside Frankfurt, privately-held drugmaker Boehringer Ingelheim revealed net sales of 17.5 billion euros ($19.8 billion) for 2018, down 3.3% from 18.1 billion euros the year before. 17 April 2019
The Pharmaceutical Price Regulation Scheme (PPRS) is dead; long live the Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme)! 16 April 2019
Global vaccines producers are losing their positions in the Russian market, due to the ever growing competition with local producers, which receive support from the state, according to recent statements of producers, reports The Pharma Letter’s local correspondent. 16 April 2019
Japan’s largest drugmaker Takeda has officially launched the production of Advate (octocog alfa) - a drug for the treatment of patients with hemophilia A - at the facilities of its Russian partner, the Moscow-based Biocad plant. 16 April 2019
Shares in US healthcare giant Johnson & Johnson were up by nearly 3% after half-an-hour's trading on Tuesday following the company’s quarterly results presentation. 16 April 2019
Financing and creating enduring confidence around a deal like Takeda’s $62 million purchase of Shire is not straight forward, but the Japanese drugmaker has hired one of the best operators in his field to help with the task. 16 April 2019
Chinese drugmaker Hansoh Pharmaceutical Group has re-filed its application for an initial public offering (IPO) in Hong Kong, according to sources quoted by Reuters. 15 April 2019
Johnson & Johnson has unveiled positive Phase III data from the CREDENCE study of Invokana (canagliflozin) at the World Congress of Nephrology in Australia. 15 April 2019
Viking Therapeutics has presented new results from the company's 12-week Phase II study of VK2809 at the International Liver Congress 2019 in Vienna. 12 April 2019
Amid the endless series of headlines about Brexit and Donald Trump, the latest appearance of the Ebola virus has not received the international attention that the previous outbreak did. 12 April 2019
USA-based liver specialist Intercept Pharmaceuticals has presented further Phase III data from the REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). 11 April 2019
AstraZeneca continues to make strides in the company’s vision to advance clinical practice from treating patients with a single disease, such as type-2 diabetes (T2D), to addressing overlapping disease areas and risk factors, such as kidney disease. 11 April 2019
The Economist Intelligence Unit (EIU) has predicted that Russia’s pharma market will grow by nearly 5% in 2019 from 2018, in US dollar terms. 11 April 2019
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.